Neuralink N2 — Expanded Clinical Programme

Invest in the future of human-computer symbiosis

Expected Yield

30%+

Min. Investment

$10,000

Raised / Goal

$19.4M / $80.0M

Days Left

64d

The Opportunity

Neuralink's N2 device programme expands the PRIME study to 50 paralysis patients across 12 sites globally, while advancing the R&D roadmap toward a second-generation implant with 10× electrode density and wireless charging. This raise supports clinical operations, device manufacturing scale-up, and regulatory pathway for FDA Breakthrough Device approval.

First BCI to achieve sustained telepathic cursor control in humans
FDA Breakthrough Device designation secured
N2 device targets 10× electrode density vs N1
50-patient PRIME expansion across 12 global sites
Licensing pipeline value estimated at $8B by independent analysts

Project Milestones

Aug 2025

PRIME study first patient implanted

Jun 2026

12-month PRIME interim data published

Sep 2026

N2 device design freeze

Jan 2027

50-patient expansion fully enrolled

Apr 2028

FDA PMA submission

Choose Your Entry Point

Selected

Explorer

$10K – $75K

Expected Return

85%–110%

Current Tier

Pioneer

$75K – $300K

Expected Return

110%–145%

Select Tier

Visionary

$300K+

Expected Return

145%–200%

Select Tier

Calculate Your Investment

Projected Return$8,500 – $82,500

Total Value$18,500 – $157,500

Based on 85%–110% projected yield for the Explorer tier. Projections are estimates, not guarantees.

Invest Now

Limited Availability

Spots across all tiers are limited. Once filled, this offering closes regardless of the deadline.